When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALLK - Allakos expands lirentelimab development into atopic dermatitis urticaria and asthma
Allakos Inc.
Allakos (ALLK +2.1%) has initiated a Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis. The company also announced plans to initiate two placebo-controlled trials of SC lirentelimab in patients with chronic spontaneous urticaria (middle of 2022) and in moderate-to-severe, uncontrolled asthma patients with and without an eosinophilic phenotype (Q4 2022).